Kevin E. Noonan, PhD

Partner with IP law firm MBHB and the co-chair of its biotechnology and pharmaceuticals practice group

Issue represents a potential threat in fighting future pandemics.

Kevin E. Noonan asks, what do the biosimilars provisions of the Trans-Pacific Partnership portend for global biologic drug development?